Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis : an analysis from VOYAGE 1 and VOYAGE 2
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Wu, Jashin (Dermatology Research and Education Foundation)
Gooderham, Melinda (SKiN Centre for Dermatology and Department of Medicine. Queen's University)
You, Yin (Biostatistics. Immunology. Janssen Research & Development. LLC)
Shen, Yaung-Kaung (Biostatistics. Immunology. Janssen Research & Development. LLC)
Randazzo, Bruce (Clinical Research. Janssen Research & Development. LLC)
Kerdel, Francisco (Florida Academic Dermatology Centers)

Date:	2021
Abstract:	Introduction: In VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244), guselkumab, an interleukin-23 blocker, was safe and effective in patients with moderate-to-severe plaque psoriasis. Methods: Patients who self-identified as Hispanic (n = 117) or non-Hispanic (n = 1686) were randomized to guselkumab, placebo, or adalimumab. Efficacy assessments included Psoriasis Area and Severity Index (PASI), Investigator's Global Assessment (IGA), and Dermatology Life Quality Index (DLQI). Results: At week 16, treatment differences for guselkumab versus placebo in the Hispanic and non-Hispanic populations were 67. 4 (95% confidence interval 50. 4, 84. 4) and 77. 2 (73. 5, 80. 8) percentage points for IGA 0/1 and 59. 2 (41. 9, 76. 4) and 69. 2 (65. 7, 72. 7) percentage points for PASI 90, respectively. Treatment differences for guselkumab versus adalimumab were 25. 9 (6. 5, 45. 3) and 17. 5 (12. 8, 22. 3) percentage points for IGA 0/1 and 21. 4 (-0. 1, 42. 9) and 23. 5 (18. 2, 28. 9) percentage points for PASI 90, respectively. Week 24 results were similar. Adverse event frequency was greater in adalimumab- versus guselkumab-treated patients in the Hispanic population only through weeks 16 and 28. In both populations, DLQI 0/1 responses were greater in guselkumab-treated versus placebo- and adalimumab-treated patients at week 16 and versus adalimumab-treated patients at week 24. Conclusions: Guselkumab safety and efficacy were consistent between Hispanic and non-Hispanic populations.
Note:	Altres ajuts: Janssen Research and Development (JRD)
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Guselkumab ; Psoriasis ; Hispanic
Published in:	Journal of Dermatological Treatment, Vol. 32 Núm. 5 (2021) , p. 484-491, ISSN 1471-1753

DOI: 10.1080/09546634.2019.1679336
PMID: 31613178

9 p, 2.0 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles